What cybersecurity challenges are unique to diabetes care devices?

Diabetes care devices often involve wireless connectivity for data transfer (e.g., from CGM to phone or pump), making them vulnerable to cybersecurity threats like data breaches, unauthorized access, and disruption of therapy delivery. Ensuring secure authentication, data encryption, and robust software updates is critical.

How does the evolving landscape of AI and machine learning impact diabetes care device regulation?

AI and machine learning are increasingly used in AID systems for dose recommendations and glycemic control. Regulators are developing specific frameworks for these technologies, focusing on data quality, algorithm validation, transparency, and continuous monitoring of performance post-market, as outlined in FDA guidance on Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan.

All terms

Market SegmentsStrategic Landscape

Diabetes Care

Devices for glucose monitoring and insulin delivery.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

Diabetes devices include continuous glucose monitors (CGM: Dexcom G7, Abbott FreeStyle Libre), insulin pumps (Tandem, Medtronic, Insulet Omnipod), automated insulin delivery (AID) closed-loop systems, and smart pens.

What the regulation says

Diabetes care MedTech products are subject to specific regulatory pathways, often designated as high-risk devices due to their direct impact on patient health. For example, in the US, continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems are typically classified as Class II or Class III devices by the FDA, requiring premarket notification (510(k)) or premarket approval (PMA) respectively, per 21 CFR Part 862.1345 for glucose monitors. The EU MDR (Regulation (EU) 2017/745) also categorizes these devices based on their intended use, generally placing them in higher risk classes, such as Class IIb or Class III, requiring notified body involvement and extensive clinical evidence. Furthermore, cybersecurity considerations are paramount for connected diabetes devices, with guidance from the FDA (e.g., "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions") and international standards like ISO/IEC 81001-5-1 addressing security, accuracy, and reliability requirements.

What this means in practice

CGM is one of MedTech's fastest-growing segments, expanding from T1D to T2D and to non-insulin-using populations. Pharmacy-channel CGM is reshaping reimbursement and access.

Examples

A manufacturer develops a new automated insulin delivery system, requiring comprehensive clinical trials to demonstrate safety and effectiveness for its Class III FDA classification and extensive cybersecurity testing due to its wireless communication features.
A company designing a smart insulin pen must ensure its accompanying mobile application complies with data privacy regulations like GDPR and HIPAA, and that the device's usability has been validated for diverse user populations, including those with limited technical proficiency.
A startup creating a non-invasive continuous glucose monitor faces stringent requirements for clinical accuracy and must demonstrate equivalence to existing invasive methods to gain regulatory approval, addressing both performance and cybersecurity aspects.

Common pitfalls

•Failing to address interoperability standards and cybersecurity risks for connected diabetes devices can lead to regulatory non-compliance and patient harm.
•Underestimating the clinical evidence required for novel diabetes care technologies, particularly for Class III devices, can significantly delay market access.
•Ignoring specific labeling and usability requirements for home-use diabetes devices can result in user errors and adverse events.
•Not accounting for the unique post-market surveillance requirements for software as a medical device (SaMD) components within diabetes care can lead to undetected safety issues.
•Assuming that a device classification in one regulatory jurisdiction automatically applies to another without detailed review can lead to significant delays and rework.

Frequently asked questions

In the US, many diabetes care devices, such as CGMs, fall under Class II (510(k) pathway) or Class III (PMA pathway) depending on their invasiveness and risk. In the EU, they are typically Class IIb or III under the MDR, requiring stringent conformity assessments.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Market Segments

Wearable Medical Devices

Body-worn devices that continuously monitor physiological signals.

Software & AI

Software as a Medical Device(SaMD)

Software intended for medical purposes that performs without being part of a hardware device.

More in Market Segments

· Same category

Market Segments

Aesthetic & Energy-Based Devices

Lasers, RF, ultrasound, cryolipolysis, and IPL systems used for medical and cosmetic indications, body contouring, hair removal, skin tightening, vascular lesions.

Market Segments

AI Imaging Software

Software that analyzes medical images to triage, detect, or quantify disease.

Market Segments

Cardiac Rhythm Management(CRM)

Implantable and external devices that monitor and treat cardiac arrhythmias, pacemakers, ICDs, CRT devices, and insertable cardiac monitors.

Market Segments

Cardiovascular Devices

Devices for diagnosing, monitoring, or treating cardiovascular disease.

Mentioned in recent activity

1 entry

Tandem pumps are battery-operated infusion pumps capable of both basal and bolus delivery of insulin. The pumps utilize a motor-driven mechanism to deliver insulin from within a disposable cartridge, through an infusion set, into a patient s subcutaneous tissue. As with current insulin infusion pumps on the U.S. market, the desired timing and quantity of the insulin delivery is programmed by the user (i.e., the patient).

Class II· 2026-01-30

Latest in MedTech

View all

Recent regulatory actions, publications, and trials matched to this term. Updated daily.

Recall2026-01-30
Tandem pumps are battery-operated infusion pumps capable of both basal and bolus delivery of insulin. The pumps utilize a motor-driven mechanism to deliver insulin from within a disposable cartridge, through an infusion set, into a patient s subcutaneous tissue. As with current insulin infusion pumps on the U.S. market, the desired timing and quantity of the insulin delivery is programmed by the user (i.e., the patient).
Class II · Tandem Diabetes Care, Inc.

Primary references

3 sources

Link health: 3 verified· last checked 2026-06-20

ADA·1MedTech Europe·1MedTech Dive·1

Inline markers like [1] jump to the matching reference above.

On this term

Category: Market Segments
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Devices for glucose monitoring and insulin delivery.

·CGM is one of MedTech's fastest-growing segments, expanding from T1D to T2D and to non-insulin-using populations.
·Pharmacy-channel CGM is reshaping reimbursement and access.

Remember this

Watch out: Failing to address interoperability standards and cybersecurity risks for connected diabetes devices can lead to regulatory non-compliance and patient harm.

Related terms

You may also need

Auto-suggested from Market Segments and shared keywords.

All Market Segments terms